logo
logo

Hera Biotech Closes Oversubscribed $1.9 Million Seed Raise For Novel Diagnostic Test For Endometriosis

Aug 24, 2022•about 3 years ago

Amount Raised

$1.9 Million

San AntonioBiotechnology

Description

San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support the company’s commercialization strategy for its category-defining non-surgical diagnostic test for endometriosis, MetriDxTM. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the US FDA.

Company Information

Company

Hera Biotech

Location

4725 COLLEGE PARK, SUITE 200

San Antonio, Texas, United States

About

Hera Biotech is a women’s health company dedicated to advancing the standard of care by addressing critical diagnostic and therapeutic deficiencies. With a vision to become the global leader in women’s health innovation, Hera’s first mission is to validate and commercialize the world’s first non-surgical method for diagnosing and staging endometriosis, transforming how this condition is detected and managed.

Related People